Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: SORAFENIB, . Treffer: 37

2022

Gkika, E; Grosu, AL; Macarulla, Mercade, T; Cubillo, Gracián, A; Brunner, TB; Schultheiß, M; Pazgan-Simon, M; Seufferlein, T; Touchefeu, Y Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Cancers (Basel). 2022; 14(6): Doi: 10.3390/cancers14061568 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Krstic, J; Reinisch, I; Schindlmaier, K; Galhuber, M; Riahi, Z; Berger, N; Kupper, N; Moyschewitz, E; Auer, M; Michenthaler, H; Nössing, C; Depaoli, MR; Ramadani-Muja, J; Usluer, S; Stryeck, S; Pichler, M; Rinner, B; Deutsch, AJA; Reinisch, A; Madl, T; Chiozzi, RZ; Heck, AJR; Huch, M; Malli, R; Prokesch, A Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism.
Sci Adv. 2022; 8(3):eabh2635 Doi: 10.1126/sciadv.abh2635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Bettinger, D; Pinato, DJ; Schultheiss, M; Sharma, R; Rimassa, L; Pressiani, T; Burlone, ME; Pirisi, M; Kudo, M; Park, JW; Buettner, N; Neumann-Haefelin, C; Boettler, T; Abbasi-Senger, N; Alheit, H; Baus, W; Blanck, O; Gerum, S; Guckenberger, M; Habermehl, D; Ostheimer, C; Riesterer, O; Tamihardja, J; Grosu, AL; Thimme, R; Brunner, TB; Gkika, E Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.
Liver Cancer. 2019; 8(4):281-294 Doi: 10.1159/000490260 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Franck, C; Rosania, R; Franke, S; Haybaeck, J; Canbay, A; Venerito, M The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Digestion. 2019; 99(2):179-184 Doi: 10.1159/000490886
Web of Science PubMed FullText FullText_MUG

 

Kroeze, SGC; Fritz, C; Basler, L; Gkika, E; Brunner, TB; Grosu, AL; Guckenberger, M Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.
Strahlenther Onkol. 2019; 195(3):199-206 Doi: 10.1007/s00066-018-01422-5
Web of Science PubMed FullText FullText_MUG

 

Scheipl, S; Liegl-Atzwanger, B; Szkandera, J; Rinner, B; Viertler, C; Friesenbichler, J; Bergovec, M; Leithner, A [Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].
Orthopade. 2019; 48(9): 776-783. Doi: 10.1007/s00132-019-03790-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Apostolidis, L; Pfeiffenberger, J; Gotthardt, D; Radeleff, B; Mehrabi, A; Schemmer, P; Jager, D; Schirmacher, P; Stremmel, W; Schulze-Bergkamen, H; Springfeld, C; Weiss, KH Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
GASTROINTEST TUMORS. 2018; 5(1-2): 38-46. Doi: 10.1159/000487635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Li, M; Su, Y; Zhang, F; Chen, K; Xu, X; Xu, L; Zhou, J; Wang, W A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Acta Biomater. 2018; 75(10):413-426 Doi: 10.1016/j.actbio.2018.05.049
Web of Science PubMed FullText FullText_MUG

 

Pearson, H; Knisely, AS; Deheragoda, M; Zacharoulis, S; Carceller, F Treatment of metastatic hepatocellular carcinoma in pediatric patients: Two case reports.
PEDIATR HEMAT ONCOL. 2018; 35(1): 90-94. Doi: 10.1080/08880018.2018.1457106
Web of Science PubMed FullText FullText_MUG

 

Schneider, C; Wallner, M; Kolesnik, E; Herbst, V; Mächler, H; Pichler, M; von Lewinski, D; Sedej, S; Rainer, PP The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.
Sci Rep. 2018; 8(1):5295-5295 Doi: 10.1038/s41598-018-23630-w [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Bettinger, D; Spode, R; Glaser, N; Buettner, N; Boettler, T; Neumann-Haefelin, C; Brunner, TB; Gkika, E; Maruschke, L; Thimme, R; Schultheiss, M Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
BMC Gastroenterol. 2017; 17(1):98 Doi: 10.1186/s12876-017-0656-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ganten, TM; Stauber, RE; Schott, E; Malfertheiner, P; Buder, R; Galle, PR; Göhler, T; Walther, M; Koschny, R; Gerken, G Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res. 2017; 23(19):5720-5728 Doi: 10.1158/1078-0432.CCR-16-0919 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lin, S; Hoffmann, K; Gao, C; Petrulionis, M; Herr, I; Schemmer, P Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
J PINEAL RES. 2017; 62(3): Doi: 10.1111/jpi.12398
Web of Science PubMed FullText FullText_MUG

 

2016

Jeric, I; Maurer, G; Cavallo, AL; Raguz, J; Desideri, E; Tarkowski, B; Parrini, M; Fischer, I; Zatloukal, K; Baccarini, M A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis.
Nat Commun. 2016; 7(12):13781-13781 Doi: 10.1038/ncomms13781 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): Doi: 10.3390/ijms17122011 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Hoffmann, K; Ganten, T; Gotthardtp, D; Radeleff, B; Settmacher, U; Kollmar, O; Nadalin, S; Karapanagiotou-Schenkel, I; von Kalle, C; Jäger, D; Büchler, MW; Schemmer, P Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
BMC Cancer. 2015; 15(11):392-392 Doi: 10.1186/s12885-015-1373-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lindner, C; Dierneder, J; Pall, G; Pirich, C; Hoffmann, M; Raderer, M; Becherer, A; Niederle, B; Lipp, R; Lind, P; Gallowitsch, H; Romeder, F; Virgolini, I [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Nuklearmedizin. 2015; 54(3):125-130 Doi: 10.3413/Nukmed-0688-14-07
Web of Science PubMed FullText FullText_MUG

 

Schultheiß, M; Bettinger, D; Neeff, HP; Brunner, TB; Thimme, R [Hepatocellular Carcinoma: therapeutic options 2015].
Dtsch Med Wochenschr. 2015; 140(14):1063-8 Doi: 10.1055/s-0041-102333
Web of Science PubMed FullText FullText_MUG

 

Stotz, M; Gerger, A; Haybaeck, J; Kiesslich, T; Bullock, MD; Pichler, M Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Anticancer Res. 2015; 35(11):5737-5744
Web of Science PubMed

 

2014

Brämswig, K; Ploner, F; Martel, A; Bauernhofer, T; Hilbe, W; Kühr, T; Leitgeb, C; Mlineritsch, B; Petzer, A; Seebacher, V; Stöger, H; Girschikofsky, M; Hochreiner, G; Ressler, S; Romeder, F; Wöll, E; Brodowicz, T Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Anticancer Drugs. 2014; 25(7):848-853 Doi: 10.1097/CAD.0000000000000108
Web of Science PubMed FullText FullText_MUG

 

Smolle, E; Taucher, V; Petru, E; Haybaeck, J Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Anticancer Res. 2014; 34(4):1519-1530
Web of Science PubMed

 

Walter, I; Wolfesberger, B; Miller, I; Mair, G; Burger, S; Gallè, B; Steinborn, R Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Oncol Rep. 2014; 31(3):1147-1156 Doi: 10.3892/or.2013.2954 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853 Doi: 10.1111/ddg.12100
Web of Science PubMed FullText FullText_MUG

 

Eisner, F; Schaberl-Moser, R; Gerger, A; Samonigg, H; Pichler, M Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Onkologie. 2013; 36(6):368-370 Doi: 10.1159/000351252 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Pfeiffenberger, J; Koschny, R; Hoffmann, K; Mehrabi, A; Schmitz, A; Radeleff, B; Stremmel, W; Schemmer, P; Ganten, TM Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Langenbecks Arch Surg. 2013; 398(8):1123-1128 Doi: 10.1007/s00423-013-1114-1
Web of Science PubMed FullText FullText_MUG

 

2012

Lin, S; Hoffmann, K; Schemmer, P Treatment of hepatocellular carcinoma: a systematic review.
Liver Cancer. 2012; 1(3-4):144-158 Doi: 10.1159/000343828 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 Doi: 10.1093/annonc/mdq648 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gerger, A; Labonte, M; Lenz, HJ Molecular predictors of response to antiangiogenesis therapies.
Cancer J. 2011; 17(2):134-141 Doi: 10.1097/PPO.0b013e318212db3c
Web of Science PubMed FullText FullText_MUG

 

Karki, P; Li, X; Schrama, D; Fliegel, L B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger.
J Biol Chem. 2011; 286(15): 13096-13105. Doi: 10.1074/jbc.M110.165134 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pinter, M; Sieghart, W; Hucke, F; Graziadei, I; Vogel, W; Maieron, A; Königsberg, R; Weissmann, A; Kornek, G; Matejka, J; Stauber, R; Buder, R; Grünberger, B; Schöniger-Hekele, M; Müller, C; Peck-Radosavljevic, M Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Aliment Pharmacol Ther. 2011; 34(8): 949-959. Doi: 10.1111/j.1365-2036.2011.04823.x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Hoffmann, K; Franz, C; Xiao, Z; Mohr, E; Serba, S; Büchler, MW; Schemmer, P Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Anticancer Res. 2010; 30(11):4503-4508
Web of Science PubMed

 

Rausch, V; Liu, L; Kallifatidis, G; Baumann, B; Mattern, J; Gladkich, J; Wirth, T; Schemmer, P; Büchler, MW; Zöller, M; Salnikov, AV; Herr, I Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Cancer Res. 2010; 70(12):5004-5013 Doi: 10.1158/0008-5472.CAN-10-0066 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Houben, R; Voigt, H; Noelke, C; Hofmeister, V; Becker, JC; Schrama, D MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
Mol Cancer Ther. 2009; 8(2):433-440 Doi: 10.1158/1535-7163.MCT-08-1051 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ploner, F; Eisterer, W Treatment of extensive disease
Wien Med Wochenschr. 2009; 159(15-16): 403-407. Doi: 10.1007/s10354-009-0690-8
PubMed FullText FullText_MUG

 

2008

Bhojani, N; Jeldres, C; Patard, JJ; Perrotte, P; Suardi, N; Hutterer, G; Patenaude, F; Oudard, S; Karakiewicz, PI Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Eur Urol. 2008; 53(5):917-930 Doi: 10.1016/j.eururo.2007.11.037
Web of Science PubMed FullText FullText_MUG

 

Hoffmann, K; Glimm, H; Radeleff, B; Richter, G; Heining, C; Schenkel, I; Zahlten-Hinguranage, A; Schirrmacher, P; Schmidt, J; Büchler, MW; Jaeger, D; von Kalle, C; Schemmer, P Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
BMC Cancer. 2008; 8(3):349-349 Doi: 10.1186/1471-2407-8-349 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pföhler, C; Ugurel, S Cutaneous reactions to molecular targeted therapies.
Hautarzt. 2008; 59(10):814-820 Doi: 10.1007/s00105-008-1540-0
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum